January 15, 2023
3 min watch
Save
VIDEO: Study results reaffirm anti-VEGF agents work for promoting regression of ROP
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, R.V. Paul Chan, MD, discusses treatment options for pediatric retinal disease and retinopathy of prematurity.
Chan recounts results from the FIREFLEYE study, a randomized clinical trial that compared aflibercept vs. laser for type 1 ROP and aggressive ROP.
“This study was very important because it basically just affirmed what we know, which is that anti-VEGF generally works for promoting regression of disease,” Chan said.
Published by:
Sources/Disclosures
Collapse
Source:
Chan RVP. Treatment of pediatric retina patients in the era of laser and anti-VEGF. Presented at: Hawaiian Eye; Jan. 14-20, 2023; Koloa, Hawaii.
Disclosures:
Chan reports consulting and advising for Alcon and Genentech, and being an owner of and having equity in Siloam Vision.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.